Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally.
The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests.
It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 8, 24 | -0.60 Decreased by -42.86% | -0.47 Decreased by -27.66% |
| Feb 21, 24 | -0.27 Increased by +62.50% | -0.46 Increased by +41.30% |
| Nov 1, 23 | 0.00 Increased by +100.51% | -0.48 Increased by +100.90% |
| Aug 1, 23 | -0.45 Increased by +45.78% | -0.51 Increased by +11.76% |
| May 9, 23 | -0.42 Increased by +59.62% | -0.75 Increased by +44.00% |
| Feb 21, 23 | -0.72 Increased by +43.75% | -0.84 Increased by +14.29% |
| Nov 3, 22 | -0.84 Increased by +13.40% | -1.08 Increased by +22.22% |
| Aug 2, 22 | -0.83 Increased by +19.42% | -1.07 Increased by +22.43% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 628.34 M Increased by +20.12% | 794.00 K Increased by +100.53% | Increased by +0.13% Increased by +100.44% |
| Jun 30, 23 | 622.09 M Increased by +19.26% | -81.03 M Increased by +51.21% | Decreased by -13.02% Increased by +59.09% |
| Mar 31, 23 | 602.45 M Increased by +23.82% | -74.15 M Increased by +59.02% | Decreased by -12.31% Increased by +66.90% |
| Dec 31, 22 | 553.00 M Increased by +16.71% | -127.75 M Increased by +42.09% | Decreased by -23.10% Increased by +50.39% |
| Sep 30, 22 | 523.07 M Increased by +14.61% | -148.76 M Increased by +10.89% | Decreased by -28.44% Increased by +22.25% |
| Jun 30, 22 | 521.64 M Increased by +19.97% | -166.06 M Increased by +6.13% | Decreased by -31.83% Increased by +21.76% |
| Mar 31, 22 | 486.57 M Increased by +21.01% | -180.94 M Decreased by -480.60% | Decreased by -37.19% Decreased by -379.77% |
| Dec 31, 21 | 473.81 M Increased by +1.60% | -220.61 M Increased by +49.49% | Decreased by -46.56% Increased by +50.29% |